StockData
Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp. (MDNAF) stock

MDNAFOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2023, year ended Mar 31, 2023Last filing: 20-F on Jun 27, 2023
$0.28−0.02 (-7.63%)

Close on Oct 19, 2026

Medicenna Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2023 it was C$9.30M, down 36.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2023Mar 31, 2023C$9.30M-36.8%
FY2022Mar 31, 2022C$14.72M+35.4%
FY2021Mar 31, 2021C$10.87M+85.2%
FY2020Mar 31, 2020C$5.87M–

More Medicenna Therapeutics figures

See a number that looks wrong?